AFRICAN AMERICAN HISTORY MONTH - Raymond F. Schinazi
Raymond F. Schinazi is an American organic medicinal chemist with expertise in antiviral agents, pharmacology, and biotechnology. Schinazi was born on March 21, 1950 in Alexandria Egypt. In 1962 his family was sequestered by the Nasser regime and in 1964 they immigrated to Naples, Italy as refugees. Schinazi went to Boarding School in the UK where he completed his early education prior to being admitted as a Chemistry major at Bath University in 1968. He received his BSc (1972) and PhD (1976) in Chemistry and DSc (Hon) (2006) in Biotechnology from the University of Bath, England. In 1976, he moved to Yale University, department of Pharmacology and trained as a postdoctoral fellow with William H. Prusoff.
Dr. Schinazi is widely considered the most prolific antiviral drug developer of all time, responsible for the discovery and/or development of five drugs used to treat HIV, HBV and HCV. Dr. Schinazi is currently the Frances Winship Professor of Pediatrics, Director of the Laboratory of Biochemical Pharmacology, and Co-Director of the HIV Cure Scientific Working Group within the NIH-sponsored Emory University Center for AIDS Research. His laboratory develops approaches to treat infections caused by HIV, HBV, HCV, herpes, influenza, Zika, West Nile, chikungunya and dengue virus, among others.
Insights from 40 years of research at Emory led Dr. Schinazi to found multiple successful biotechnology companies, including Pharmasset, Inc. (VRUS; acquired by Gilead for $11.4 billion in 2012), Idenix Pharmaceuticals (IDIX; acquired by Merck for $3.9 billion in 2014) and Triangle Pharmaceuticals (VIRS; acquired by Gilead for $464 million in 2003). In 2014, Dr. Schinazi also led the merger of his namesake RFS Pharma with CoCrystal Pharma (COCP), where he now serves as Chairman of the Board.
In addition to his work at Emory University, Dr. Schinazi spent 35 years at the Atlanta Department of Veterans Affairs, most recently in the role of Senior Research Career Scientist for which he received the 2015 William S. Middleton Award, the highest honor of the Veterans Affairs Biomedical Laboratory Research and Development Service. He also serves as Governing Trustee for the Foundation of AIDS Research (amfAR), The International Centre for Missing and Exploited Children (ICMEC) and on the Board of the Global Virus Network (GVN). In addition to his role as Chairman of the Board of Cocrystal Pharma, Dr. Schinazi is Director of Brace Pharmaceuticals, Inc., non-executive Director of Gliknik Inc., and non-executive Director of reViral Ltd. Since receiving his BSc (1972) and PhD (1976) in chemistry from the University of Bath in England, Dr. Schinazi has authored more than 500 peer-reviewed papers and seven books and holds over 100 issued U.S. patents and over 120 non-U.S. national stage patents and patent applications, which have resulted in 20 New Drug Applications.
Attachments: